|  |  |  |  |
| --- | --- | --- | --- |
|   | **MDD/MRD cohort (n=82)** | **Total French T-LL cohort****(n=205)** | **p-value** |
|   | Median age (years, range) | 10.1 (0.5-17.7) | 10.1 (0.1-18.8) | p=0.956 |
|   | Gender (M, %) | 62 (76%) | 157 (77%) | p=0.982 |
|   | Stage (n=) | (n=80) | (n=202) | p=0.315 |
|   | I/II | 8 (10%) | 10 (5%) |  |
|   | III | 55 (69%) | 148 (73%) |  |
|   | IV | 17 (21%) | 44 (22%) |  |
|   | CNS involvement (Yes, %) | 6/79 (8%) | 10/200 (5%) | p=0.401 |
|   | BM involvement (Yes, %) | 14/79 (18%) | 35/195 (18%) | p=1.00 |
|   | Relapse (Yes, %) | 7 (8.5%) | 28 (13.7) | p=0.318 |
|  | 5y-OS (%, 95% CI) | 89.0% [0.825, 0.961] | 87.0% [0.823, 0.921] | p=0.64 |
|   | 5y-EFS (%, 95% CI) | 87.8% [0.810, 0.952] | 88.0% [0.835, 0.927] | p=0.97 |

**Table S1**